Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Valeant Acquires Dermik Dermatology Business from Sanofi - Happi
Company News

Valeant Acquires Dermik Dermatology Business from Sanofi

Canadian pharma company has global rights to Hissyfit, Dr. LeWinn's.

Sanofi has sold its Dermik dermatology business to Valeant Pharmaceuticals International in a $425 million deal.

Based in Mississauga, Ontario, Canada,Valeant is apharmaceutical company thatalso sells and owns consumer and OTC products including Hissyfit, an anti-aging skin care line,Dr. LeWinn’s Private Formula, a premium skin care line, and Revitanail (Renunail in the U.S. and United Kingdom), a line of nail strengtheners. Its stable also includes Private Formula International Holdings Pty Limited, a leading skin care company in Australia and New Zealand and Reef skin care in Australia.

Dermik has a significant presence in the medical dermatology market in the United States and Canada with a strong field force and well-known brands. Dermik’s portfolio includes leading therapeutic and aesthetic dermatology brands such as BenzaClin for the treatment of acne and Sculptra, a facial injectable for the correction of facial wrinkles and folds.

The scope of this transaction includes Dermik assets, which consist of an aesthetic and therapeutic business in the US and Canada, as well as an aesthetic business around the world with sales of $206 million in 2010. Also included in the scope is Sanofi’s Laval, Canada site, which includes Dermik’s manufacturing facility.

Sanofi’s Canadian affiliate, sanofi-aventis Canada, will maintain its operations in greater Montreal, the company said.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters